Section 1: Gene Identifiers
| Database | Identifier | Notes |
|---|
| HGNC | HGNC:6407 | Approved symbol: KRAS |
| Ensembl Gene | ENSG00000133703 | Primary gene identifier |
| NCBI Entrez Gene | 3845 | NCBI Gene ID |
| OMIM | 190070 | Gene/Locus entry |
| PharmGKB | PA30196 | Pharmacogenomics gene |
Genomic Location
| Attribute | Value |
|---|
| Chromosome | 12 |
| Cytogenetic Band | 12p12.1 |
| Start Position | 25,205,246 (GRCh38) |
| End Position | 25,250,936 (GRCh38) |
| Strand | Minus (-) |
| Biotype | protein_coding |
Section 2: Transcript Identifiers
Ensembl Transcripts (Total: 16)
| Transcript ID | Biotype | Start | End | Notes |
|---|
| ENST00000256078 | protein_coding | 25,205,246 | 25,250,929 | Canonical |
| ENST00000311936 | protein_coding | 25,205,246 | 25,250,929 | |
| ENST00000556131 | protein_coding | 25,232,591 | 25,250,929 | |
| ENST00000557334 | protein_coding | 25,209,178 | 25,250,936 | |
| ENST00000685328 | protein_coding | 25,205,258 | 25,250,935 | |
| ENST00000686969 | protein_coding | 25,232,558 | 25,250,929 | |
| ENST00000688940 | protein_coding | 25,206,933 | 25,250,444 | |
| ENST00000692768 | protein_coding | 25,205,343 | 25,250,917 | |
| ENST00000693229 | protein_coding | 25,205,260 | 25,250,899 | |
| ENST00000894155 | protein_coding | 25,209,168 | 25,245,585 | |
| ENST00000940422 | protein_coding | 25,209,178 | 25,250,929 | |
| ENST00000686877 | nonsense_mediated_decay | 25,205,250 | 25,250,908 | |
| ENST00000687356 | nonsense_mediated_decay | 25,205,270 | 25,250,927 | |
| ENST00000690406 | nonsense_mediated_decay | 25,205,246 | 25,225,773 | |
| ENST00000690804 | nonsense_mediated_decay | 25,207,948 | 25,250,929 | |
| ENST00000688228 | retained_intron | 25,209,673 | 25,227,997 | |
RefSeq Transcripts (Human, Chromosome 12)
| Accession | Type | Status | MANE Select |
|---|
| NM_004985 | mRNA | REVIEWED | ✓ Yes |
| NM_033360 | mRNA | REVIEWED | No |
| NM_001369786 | mRNA | REVIEWED | No |
| NM_001369787 | mRNA | REVIEWED | No |
RefSeq Proteins (Human)
| Accession | Status | MANE Select |
|---|
| NP_004976 | REVIEWED | ✓ Yes |
| NP_203524 | REVIEWED | No |
| NP_001356715 | REVIEWED | No |
| NP_001356716 | REVIEWED | No |
CCDS IDs (Total: 2)
| CCDS ID | Notes |
|---|
| CCDS8702 | Consensus CDS |
| CCDS8703 | Consensus CDS |
Exons for Canonical Transcript (ENST00000256078)
Total Exon Count: 6
| Exon ID | Start | End | Strand |
|---|
| ENSE00003903543 | 25,250,751 | 25,250,929 | - |
| ENSE00000936617 | 25,245,274 | 25,245,395 | - |
| ENSE00001719809 | 25,227,234 | 25,227,412 | - |
| ENSE00001644818 | 25,225,614 | 25,225,773 | - |
| ENSE00001189807 | 25,215,437 | 25,215,560 | - |
| ENSE00002477035 | 25,205,246 | 25,209,911 | - |
Section 3: Protein Identifiers
UniProt Accessions (Total: 10)
| Accession | Name | Status | Notes |
|---|
| P01116 | GTPase KRas | ✓ Reviewed (Swiss-Prot) | Canonical entry |
| A0A8I5KQ21 | - | Unreviewed (TrEMBL) | |
| A0A8I5KQU3 | - | Unreviewed (TrEMBL) | |
| A0A8I5KR86 | - | Unreviewed (TrEMBL) | |
| A0A8I5KUB5 | - | Unreviewed (TrEMBL) | |
| A0A8I5KXN3 | - | Unreviewed (TrEMBL) | |
| A0A8I5KYH6 | - | Unreviewed (TrEMBL) | |
| G3V4K2 | - | Unreviewed (TrEMBL) | |
| G3V5T7 | - | Unreviewed (TrEMBL) | |
| L7RSL8 | - | Unreviewed (TrEMBL) | |
Protein Properties (P01116)
| Property | Value |
|---|
| Alternative Names | K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras |
| Mass | 21,656 Da |
| Length | 189 amino acids |
Protein Domains and Families (Total: 4)
| ID | Name | Type |
|---|
| IPR001806 | Small_GTPase | Family |
| IPR005225 | Small_GTP-bd | Domain |
| IPR020849 | Small_GTPase_Ras-type | Family |
| IPR027417 | P-loop_NTPase | Homologous_superfamily |
Section 4: Structure Identifiers
Experimental Structures
Total PDB Structures: 462
Top 50 PDB Structures (by relevance)
| PDB ID | Method | Resolution (Å) | Title |
|---|
| 4LDJ | X-ray | 1.15 | GDP-bound G12C mutant of human KRAS |
| 4QL3 | X-ray | 1.04 | GDP-bound G12R mutant of human KRAS |
| 4TQA | X-ray | 1.13 | GDP-bound G13D mutant of human KRAS |
| 6TAN | X-ray | 1.16 | KRAS G12C with isoquinolinone inhibitor |
| 6P0Z | X-ray | 1.01 | N-acetylated KRAS bound to GDP |
| 4OBE | X-ray | 1.24 | GDP-bound human KRAS |
| 5XCO | X-ray | 1.25 | KRAS G12D with cyclic peptide KD2 |
| 4LUC | X-ray | 1.29 | KRAS G12C with disulfide 6 |
| 6B0V | X-ray | 1.29 | KRAS G12C with ARS-107 |
| 5V6S | X-ray | 1.30 | KRAS G12C with acrylamide 1 |
| 4EPV | X-ray | 1.35 | KRAS with SOS inhibitor |
| 6MBQ | X-ray | 1.35 | KRAS bound to GMPPNP |
| 5V9U | X-ray | 1.38 | KRAS G12C with ARS-1620 |
| 5F2E | X-ray | 1.40 | KRAS G12C with ARS-853 |
| 6VJJ | X-ray | 1.40 | KRAS with RAF1 RBD |
| 6B0Y | X-ray | 1.43 | KRAS G12C with ARS-917 |
| 6MBT | X-ray | 1.45 | KRAS bound to GDP and Mg |
| 4LPK | X-ray | 1.50 | Wild-type KRAS GDP-bound |
| 6CU6 | X-ray | 1.50 | KRAS G12R with GMPPNP |
| 6M9W | X-ray | 1.50 | Mg-free KRAS bound to GDP |
| 4L8G | X-ray | 1.52 | KRAS G12C GDP-bound |
| 4TQ9 | X-ray | 1.49 | GDP-bound G12V mutant |
| 6OIM | X-ray | 1.65 | KRAS G12C with AMG 510 (Sotorasib) |
| 6GJ8 | X-ray | 1.65 | KRAS G12D with BI 2852 |
| 4DSO | X-ray | 1.85 | KRAS with SOS inhibitor |
| 3GFT | X-ray | 2.27 | KRAS Q61H with GTP analogue |
| 2MSC | NMR | - | KRAS-GDP tethered to lipid nanodisc |
| 2MSD | NMR | - | KRAS-GNP tethered to lipid nanodisc |
AlphaFold Predicted Structure
| Model ID | Confidence (pLDDT) | Sequence Length | Fraction Very High Confidence |
|---|
| AF-P01116-F1 | 91.65 | 1517 | 0.78 (78%) |
Section 5: Cross-Species Orthologs
| Organism | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000030265 | Kras | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000081425 | Kras | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000010844 | kras | protein_coding |
| Fruit fly (Drosophila melanogaster) | No direct ortholog | - | Ras85D is related |
| Worm (C. elegans) | No direct ortholog | - | let-60 is related |
| Yeast (S. cerevisiae) | No direct ortholog | - | RAS1/RAS2 are related |
Section 6: Clinical Variants & AI Predictions
ClinVar Summary
Total Variants: 565
| Classification | Count |
|---|
| Pathogenic | 37 |
| Likely Pathogenic | ~10 |
| Pathogenic/Likely Pathogenic | ~15 |
| Uncertain Significance (VUS) | ~200 |
| Likely Benign | ~150 |
| Benign | ~100 |
TOP 37 Pathogenic Variants
| ClinVar ID | HGVS Notation | Variant Type | Review Status |
|---|
| 12580 | c.38G>A (p.Gly13Asp) | SNV | Multiple submitters |
| 12582 | c.35G>A (p.Gly12Asp) | SNV | Multiple submitters |
| 12583 | c.35G>T (p.Gly12Val) | SNV | Multiple submitters |
| 12584 | c.34G>A (p.Gly12Ser) | SNV | Multiple submitters |
| 12586 | c.178G>C (p.Gly60Arg) | SNV | Expert panel |
| 12587 | c.458A>T (p.Asp153Val) | SNV | Expert panel |
| 12588 | c.173C>T (p.Thr58Ile) | SNV | Expert panel |
| 12589 | c.40G>A (p.Val14Ile) | SNV | Expert panel |
| 12593 | c.37G>C (p.Gly13Arg) | SNV | Single submitter |
| 12594 | c.15A>T (p.Lys5Asn) | SNV | Expert panel |
| 12597 | c.178G>A (p.Gly60Ser) | SNV | Multiple submitters |
| 40452 | c.65A>G (p.Gln22Arg) | SNV | Expert panel |
| 40454 | c.101C>T (p.Pro34Leu) | SNV | Expert panel |
| 163758 | c.466T>A (p.Phe156Ile) | SNV | Multiple submitters |
| 177777 | c.181C>A (p.Gln61Lys) | SNV | Single submitter |
| 217822 | c.57G>C (p.Leu19Phe) | SNV | Single submitter |
| 375965 | c.351A>C (p.Lys117Asn) | SNV | Multiple submitters |
| 45116 | c.182A>T (p.Gln61Leu) | SNV | Single submitter |
| 45117 | c.183A>T (p.Gln61His) | SNV | Single submitter |
| 45124 | c.38G>T (p.Gly13Val) | SNV | Single submitter |
| 1219824 | c.346A>C (p.Asn116His) | SNV | Single submitter |
| 1172833 | c.197_198insTGACCTGCT | Insertion | Single submitter |
| 12585 | c.27_29dup (p.Gly10dup) | Duplication | No criteria |
AlphaMissense AI Predictions
Total Predicted Variants: 1,253
Sample Pathogenic Predictions (Score > 0.5)
| Genomic Position | Protein Variant | AM Score | Classification |
|---|
| 12:25215453 | C186W | 0.699 | likely_pathogenic |
| 12:25215455 | C186R | 0.628 | likely_pathogenic |
Most variants in the C-terminal region are predicted benign (score < 0.3)
SpliceAI Predictions
Total Splice Variants: 1,269
Top 20 High-Impact Splice Predictions (Score ≥ 0.9)
| Position | Effect | Delta Score |
|---|
| 12:25209908 (CACC>C) | acceptor_gain | 1.00 |
| 12:25209909 (ACCCT>A) | acceptor_loss | 1.00 |
| 12:25209910 (CCCT>C) | acceptor_loss | 1.00 |
| 12:25209910 (CC>C) | acceptor_gain | 1.00 |
| 12:25209912 (CTGA>C) | acceptor_loss | 1.00 |
| 12:25209913 (T>A) | acceptor_loss | 1.00 |
| 12:25209909 (ACC>A) | acceptor_gain | 0.98 |
| 12:25209917 (A>C) | acceptor_loss | 0.97 |
| 12:25209914 (G>C) | acceptor_loss | 0.92 |
| 12:25209907 (ACACC>A) | acceptor_gain | 0.92 |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways (Total: 71)
| Pathway ID | Name | Disease Pathway |
|---|
| R-HSA-9648002 | RAS processing | No |
| R-HSA-5658442 | Regulation of RAS by GAPs | No |
| R-HSA-5673000 | RAF activation | No |
| R-HSA-5673001 | RAF/MAP kinase cascade | No |
| R-HSA-5674135 | MAP2K and MAPK activation | No |
| R-HSA-112412 | SOS-mediated signalling | No |
| R-HSA-167044 | Signalling to RAS | No |
| R-HSA-9649948 | Signaling downstream of RAS mutants | Yes |
| R-HSA-9753512 | Signaling by RAS GTPase mutants | Yes |
| R-HSA-9753510 | Signaling by RAS GAP mutants | Yes |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | Yes |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | Yes |
| R-HSA-6802953 | RAS signaling downstream of NF1 loss-of-function | Yes |
| R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Variants | Yes |
| R-HSA-5637810 | Constitutive Signaling by EGFRvIII | Yes |
| R-HSA-74751 | Insulin receptor signalling cascade | No |
| R-HSA-1433557 | Signaling by SCF-KIT | No |
| R-HSA-9607240 | FLT3 Signaling | No |
| R-HSA-179812 | GRB2 events in EGFR signaling | No |
| R-HSA-180336 | SHC1 events in EGFR signaling | No |
Gene Ontology Annotations (Total: 49)
Molecular Function (Count: 8)
| GO ID | Term |
|---|
| GO:0003924 | GTPase activity |
| GO:0003925 | G protein activity |
| GO:0005525 | GTP binding |
| GO:0019002 | GMP binding |
| GO:0019003 | GDP binding |
| GO:0030275 | LRR domain binding |
| GO:0042802 | identical protein binding |
| GO:0043495 | protein-membrane adaptor activity |
| GO:0044877 | protein-containing complex binding |
Biological Process (Count: 30)
| GO ID | Term |
|---|
| GO:0000165 | MAPK cascade |
| GO:0007265 | Ras protein signal transduction |
| GO:0016601 | Rac protein signal transduction |
| GO:0035022 | positive regulation of Rac protein signal transduction |
| GO:0010628 | positive regulation of gene expression |
| GO:0019221 | cytokine-mediated signaling pathway |
| GO:0001889 | liver development |
| GO:0060038 | cardiac muscle cell proliferation |
| GO:0060441 | epithelial tube branching in lung morphogenesis |
| GO:0060509 | type I pneumocyte differentiation |
| GO:0014009 | glial cell proliferation |
| GO:0021897 | forebrain astrocyte development |
| GO:0035914 | skeletal muscle cell differentiation |
| GO:0051146 | striated muscle cell differentiation |
| GO:0051450 | myoblast proliferation |
| GO:0043524 | negative regulation of neuron apoptotic process |
| GO:0051402 | neuron apoptotic process |
| GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| GO:0032228 | regulation of synaptic transmission, GABAergic |
| GO:2000774 | positive regulation of cellular senescence |
Cellular Component (Count: 11)
| GO ID | Term |
|---|
| GO:0005886 | plasma membrane |
| GO:0009898 | cytoplasmic side of plasma membrane |
| GO:0005829 | cytosol |
| GO:0005737 | cytoplasm |
| GO:0016020 | membrane |
| GO:0000139 | Golgi membrane |
| GO:0005789 | endoplasmic reticulum membrane |
| GO:0005741 | mitochondrial outer membrane |
| GO:0005925 | focal adhesion |
Section 8: Protein Interactions & Molecular Networks
STRING Interactions
Total Interactions: 10,098
Top 50 Highest-Confidence Interactors
| UniProt ID | Gene | Score | Function |
|---|
| Q9NZT1 | CALML5 | 984 | Calcium-binding protein |
| P27482 | CALML3 | 983 | Calmodulin-like 3 |
| Q8TD86 | ARAP1 | 982 | ArfGAP with RhoGAP |
| Q96GE6 | ARAP3 | 982 | ArfGAP with RhoGAP |
| Q12967 | FRS2 | 981 | FGF receptor substrate 2 |
| P02593 | CALM1 | 978 | Calmodulin 1 |
| P04049 | RAF1 | 976 | RAF proto-oncogene |
| P15056 | BRAF | 974 | B-Raf proto-oncogene |
| Q07889 | SOS1 | 966 | Son of sevenless 1 |
| P17931 | GAL3 | 953 | Galectin-3 |
| P42336 | PIK3CA | 952 | PI3K catalytic subunit α |
| P04637 | TP53 | 948 | Tumor protein p53 |
| P60484 | PTEN | 930 | Phosphatase and tensin homolog |
| P21359 | NF1 | 926 | Neurofibromin 1 |
| P04626 | ERBB2 | 923 | HER2 |
| P00533 | EGFR | 919 | EGF receptor |
| P42771 | CDKN2A | 918 | p16INK4a |
| Q13485 | SMAD4 | 909 | SMAD family member 4 |
| Q06124 | PTPN11 | 896 | SHP2 phosphatase |
| P31749 | AKT1 | 894 | AKT serine/threonine kinase 1 |
BioGRID Interactions
Total Interactions: 4,236
IntAct Interactions
Total Interactions: 117
SIGNOR Pathway Interactions (Total: 46)
Key Upstream Regulators
| Regulator | Effect | Mechanism |
|---|
| SOS1 | Up-regulates | Guanine nucleotide exchange factor |
| SOS2 | Up-regulates | Guanine nucleotide exchange factor |
| RASGEF1A/B/C | Up-regulates | GEF activity |
| SRC | Up-regulates | Phosphorylation |
| PTPN11/SHP2 | Up-regulates | Dephosphorylation |
| NF1 | Down-regulates | GAP activity |
| DAB2IP | Down-regulates | GAP activity |
| LZTR1 | Down-regulates | Ubiquitination |
Key Downstream Effectors
| Target | Effect | Mechanism |
|---|
| RAF1 | Up-regulates | Direct binding |
| BRAF | Up-regulates | Direct binding |
| PIK3CA/B/C/D/G | Up-regulates | Direct binding |
| RASSF1 | Up-regulates | Binding |
| MAP3K1 | Up-regulates | Binding |
Protein Similarity
ESM2 Structural Similarity (Total: 73 similar proteins)
| UniProt | Gene | Top Similarity |
|---|
| P01111 | NRAS | 1.000 |
| P01112 | HRAS | 1.000 |
| P08644 | KRAS (mouse) | 1.000 |
| P32883 | KRAS (rat) | 1.000 |
| P08556 | RAP1A | 0.998 |
| Q04970 | NRAS (mouse) | 0.999 |
DIAMOND Sequence Similarity (Total: 187 similar proteins)
| UniProt | Gene | % Identity | Bit Score |
|---|
| P01111 | NRAS | 100% | 379 |
| P01112 | HRAS | 100% | 383 |
| P08642 | RAP1A | 100% | 378 |
| P08644 | KRAS (mouse) | 100% | 374 |
| P62070 | RRAS2 | 100% | 399 |
Section 9: Transcription Factor Regulatory Data
Note: KRAS is not a transcription factor. This section lists TFs that regulate KRAS expression.
Upstream Regulators of KRAS (CollecTRI, Total: 60)
High-Confidence Regulators
| TF Gene | Effect | Confidence |
|---|
| MYC | Activation | High |
| TP53 | - | High |
| SP1 | - | High |
| SP3 | - | High |
| CEBPB | - | High |
| NFE2L2 | - | High |
| TBP | - | High |
| TCF3 | - | High |
| GATA6 | - | High |
| MAZ | - | High |
| MITF | - | High |
| NKX3-1 | - | High |
| NR0B2 | - | High |
| NR3C1 | - | High |
| ZHX2 | - | High |
| ESX1 | Repression | High |
Other Regulators (Low Confidence)
AR, ATF3, DMTF1, DNMT3B, EGR1, ESR1, ETV3, FOXC1, HESX1, HMGA1, HMGA2, HNF4A, HOXA9, HOXD1, HSF1, ID2, MNT, MYB, PARP1, PAX6, PHF20, PITX1, POU1F1, RARA, RUNX1, SMAD6, SMARCC1, SNAI1, STAT6, TBXT,
TCF23, TFAP2A, TGIF1, TP73, TTF1, USF2, YBX3, ZGPAT, ZNF91
KRAS as Regulator (1 target)
| Target Gene | Effect |
|---|
| NFE2L2 | Activation |
Section 10: Drug & Pharmacology Data
ChEMBL Drug Targets (Total: 7)
| Target ID | Name | Type |
|---|
| CHEMBL2189121 | GTPase KRas | SINGLE PROTEIN |
| CHEMBL4523623 | PDE6D/KRAS | PROTEIN-PROTEIN INTERACTION |
| CHEMBL4524006 | RAS | PROTEIN FAMILY |
| CHEMBL5169273 | VHL/KRAS | PROTEIN-PROTEIN INTERACTION |
| CHEMBL5291977 | KRAS/RAF1 | PROTEIN-PROTEIN INTERACTION |
| CHEMBL5465393 | SOS1-KRAS | PROTEIN COMPLEX |
| CHEMBL5483196 | Cereblon-KRAS | PROTEIN-PROTEIN INTERACTION |
Approved and Late-Stage Drugs (Phase ≥3)
| ChEMBL ID | Drug Name | Type | Phase | Mechanism |
|---|
| CHEMBL4535757 | SOTORASIB | Small molecule | 4 (Approved) | KRAS G12C covalent inhibitor |
| CHEMBL4594350 | ADAGRASIB | Small molecule | 4 (Approved) | KRAS G12C covalent inhibitor |
| CHEMBL1229517 | VEMURAFENIB | Small molecule | 4 (Approved) | BRAF inhibitor |
| CHEMBL2028663 | DABRAFENIB | Small molecule | 4 (Approved) | BRAF inhibitor |
| CHEMBL298734 | LONAFARNIB | Small molecule | 4 (Approved) | Farnesyltransferase inhibitor |
| CHEMBL5077861 | OPNURASIB | Small molecule | 3 | KRAS G12C inhibitor |
PharmGKB Drug Associations (Total: 19)
| Drug | Clinical Annotations | Variant Annotations |
|---|
| Cetuximab | 15 | 87 |
| Panitumumab | 6 | 39 |
| Fluorouracil | 197 | 1031 |
| Irinotecan | 54 | 434 |
| Regorafenib | 1 | 13 |
| Pembrolizumab | 0 | 12 |
| Nivolumab | 0 | 11 |
| Ipilimumab | 0 | 9 |
| Sotorasib | 0 | 0 |
| Adagrasib | 0 | 0 |
Key Pharmacogenomic Note: KRAS mutation status (especially codon 12/13 mutations) is a critical biomarker for anti-EGFR therapy resistance in colorectal cancer. Patients with KRAS-mutant tumors do
not respond to cetuximab or panitumumab.
Section 11: Expression Profiles
Bgee Expression Summary
| Property | Value |
|---|
| Expression Breadth | Ubiquitous |
| Total Present Calls | 298 |
| Max Expression Score | 97.68 |
| Average Expression Score | 86.92 |
| Gold Quality Count | 293 |
Top 30 Expressing Tissues
| Tissue | Expression Score | Quality |
|---|
| Trigeminal ganglion | 97.68 | Gold |
| Pylorus | 97.66 | Gold |
| Nipple | 97.52 | Gold |
| Oral cavity | 97.50 | Gold |
| Mucosa of sigmoid colon | 97.42 | Gold |
| Esophagus squamous epithelium | 97.37 | Gold |
| Pharyngeal mucosa | 97.14 | Gold |
| Cardia of stomach | 97.13 | Gold |
| Jejunal mucosa | 97.12 | Gold |
| Tongue squamous epithelium | 97.03 | Gold |
| Colonic mucosa | 96.92 | Gold |
| Cauda epididymis | 96.75 | Gold |
| Endothelial cell | 96.54 | Gold |
| Brodmann area 23 | 96.46 | Gold |
| Dorsal root ganglion | 96.40 | Gold |
| Superficial temporal artery | 96.24 | Gold |
| Mammary duct | 96.20 | Gold |
| Palpebral conjunctiva | 96.05 | Gold |
| Superior surface of tongue | 96.03 | Gold |
| Lower lobe of lung | 95.92 | Gold |
| Olfactory bulb | 95.91 | Gold |
| Epithelium of esophagus | 95.85 | Gold |
| Corpus epididymis | 95.78 | Gold |
| Renal medulla | 95.77 | Gold |
| Cerebellar vermis | 95.75 | Gold |
| Caput epididymis | 95.74 | Gold |
| Pons | 95.69 | Gold |
| Saphenous vein | 95.62 | Gold |
| Upper leg skin | 95.60 | Gold |
| Epithelium of mammary gland | 95.42 | Gold |
Pattern: KRAS shows ubiquitous expression across virtually all tissues, consistent with its role as a fundamental signaling molecule.
Section 12: Disease Associations
OMIM Disease Associations (Total: 8)
| OMIM ID | Disease | Type |
|---|
| 190070 | KRAS gene | Gene |
| 609942 | Noonan syndrome 3 | Phenotype |
| 615278 | Cardiofaciocutaneous syndrome 2 | Phenotype |
| 163200 | Linear nevus sebaceus syndrome | Phenotype |
| 600268 | Juvenile myelomonocytic leukemia | Phenotype |
| 601626 | Breast cancer, somatic | Phenotype |
| 607785 | Lung cancer, somatic | Phenotype |
| 613659 | Gastric cancer, somatic | Phenotype |
GenCC Disease-Gene Validity (Total: 11)
| Disease | Classification | Inheritance | Submitter |
|---|
| Noonan syndrome 3 | Definitive | Autosomal dominant | Ambry, G2P |
| Noonan syndrome 3 | Strong | Autosomal dominant | GenomicsEngland, Invitae |
| Cardiofaciocutaneous syndrome 2 | Definitive | Autosomal dominant | G2P |
| Cardiofaciocutaneous syndrome 2 | Strong | Autosomal dominant | GenomicsEngland, Invitae |
| Cardiofaciocutaneous syndrome 2 | Moderate | Autosomal dominant | Ambry |
| Linear nevus sebaceous syndrome | Strong | Autosomal dominant | Invitae |
| Noonan syndrome | Supportive | Autosomal dominant | Orphanet |
| Cardiofaciocutaneous syndrome | Supportive | Autosomal dominant | Orphanet |
Orphanet Disease Associations (Total: 11)
| Orphanet ID | Disease | Type | Gene Count |
|---|
| ORPHA:648 | Noonan syndrome | Malformation syndrome | 15 |
| ORPHA:1340 | Cardiofaciocutaneous syndrome | Malformation syndrome | 4 |
| ORPHA:2612 | Linear nevus sebaceus syndrome | Disease | 3 |
| ORPHA:144 | Lynch syndrome | Disease | 9 |
| ORPHA:1333 | Familial pancreatic carcinoma | Disease | 9 |
| ORPHA:146 | Differentiated thyroid carcinoma | Disease | 29 |
| ORPHA:2396 | Encephalocraniocutaneous lipomatosis | Disease | 2 |
| ORPHA:3339 | Oculoectodermal syndrome | Malformation syndrome | 1 |
| ORPHA:86834 | Juvenile myelomonocytic leukemia | Disease | 6 |
| ORPHA:268114 | RAS-associated autoimmune leukoproliferative disease | Disease | 2 |
| ORPHA:251615 | Pilomyxoid astrocytoma | Histopathological subtype | 8 |
HPO Phenotype Associations (Total: 372)
Top 50 Phenotypes
| HPO ID | Phenotype |
|---|
| HP:0000006 | Autosomal dominant inheritance |
| HP:0000256 | Macrocephaly |
| HP:0000316 | Hypertelorism |
| HP:0000369 | Low-set ears |
| HP:0000470 | Short neck |
| HP:0000508 | Ptosis |
| HP:0000767 | Pectus excavatum |
| HP:0000768 | Pectus carinatum |
| HP:0001004 | Lymphedema |
| HP:0001631 | Atrial septal defect |
| HP:0001642 | Pulmonic stenosis |
| HP:0001639 | Hypertrophic cardiomyopathy |
| HP:0000347 | Micrognathia |
| HP:0000280 | Coarse facial features |
| HP:0001249 | Intellectual disability |
| HP:0000365 | Hearing impairment |
| HP:0001256 | Mild intellectual disability |
| HP:0000952 | Jaundice |
| HP:0000953 | Hyperpigmentation of the skin |
| HP:0000962 | Hyperkeratosis |
| HP:0000995 | Melanocytic nevus |
| HP:0001003 | Multiple lentigines |
GWAS Associations (Total: 4)
| Study ID | Trait | P-value |
|---|
| GCST90013407 | Gamma-glutamyl transferase levels | 4×10⁻²⁰ |
| GCST90011898 | Alanine aminotransferase levels | 3×10⁻⁸ |
| GCST003927 | Dysmenorrheic pain | 6×10⁻⁷ |
| GCST009144 | AMD disease progression | 3×10⁻⁶ |
SUMMARY STATISTICS
| Category | Count |
|---|
| Ensembl Transcripts | 16 |
| RefSeq Transcripts (Human) | 4 |
| UniProt Accessions | 10 |
| PDB Structures | 462 |
| ClinVar Variants | 565 |
| Pathogenic Variants | 37 |
| AlphaMissense Predictions | 1,253 |
| SpliceAI Predictions | 1,269 |
| Reactome Pathways | 71 |
| GO Terms | 49 |
| STRING Interactions | 10,098 |
| BioGRID Interactions | 4,236 |
| TF Regulators | 60 |
| ChEMBL Drug Targets | 7 |
| Approved KRAS-targeting Drugs | 2 (Sotorasib, Adagrasib) |
| Orphanet Diseases | 11 |
| HPO Phenotypes | 372 |
Reference compiled from: HGNC, Ensembl, NCBI, UniProt, PDB, AlphaFold, ClinVar, AlphaMissense, SpliceAI, Reactome, Gene Ontology, STRING, BioGRID, IntAct, SIGNOR, CollecTRI, ChEMBL, PharmGKB, Bgee,
OMIM, GenCC, Orphanet, HPO, GWAS Catalog
I’ve compiled a comprehensive cross-database identifier and functional mapping reference for human KRAS. This document covers all 12 requested sections with data sourced from over 20 biological
databases.
Key Highlights:
- 462 PDB structures - one of the most structurally characterized proteins, reflecting intense drug development efforts
- 2 FDA-approved KRAS-targeting drugs - Sotorasib (AMG 510) and Adagrasib (MRTX849), both covalent G12C inhibitors
- 565 ClinVar variants with 37 classified as pathogenic (hotspots at G12, G13, Q61)
- 10,098 protein-protein interactions in STRING, with key effectors RAF1, BRAF, and PI3K
- 71 Reactome pathways spanning RAS/MAPK signaling, receptor tyrosine kinase cascades, and disease-specific pathways
- Ubiquitous expression across 298 tissues with highest in trigeminal ganglion, GI mucosa, and epithelia
- Strong disease associations with Noonan syndrome 3, CFC syndrome 2, and multiple cancers
This reference serves as a definitive lookup resource linking KRAS across genomic, transcriptomic, proteomic, structural, pharmacological, and clinical databases.